Pieris stock: buy or sell?
August 22nd, 2019
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Should I buy Pieris stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Pieris stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Pieris stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 5 ratings published for PIRS stock in the last 30 days. The general sentiment of these ratings is bullish for PIRS stock, with 4 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-30||Robert W. Baird||Outperform||Neutral|
Pieris stock analysis
Pieris shares collapsed -5.61% to $4.54 yesterday.
Pieris shares collapsed -5.61% to $4.54 yesterday. On Jul 12th, SMA100d and SMA200d crossed up triggering a rise of 2.71%. Since May when PIRS stock price broke up the SMA200d line, it gained $0.79 (21.07%).
Pieris Pharmaceuticals closed this week at $4.54 and plummed a frightening -9.20%. Late July PIRS skyrocketed an extraordinary 14.41% in just one week. For 3 weeks in a row, price slid and lost a -21.26%.
Pieris stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since SMA20w and SMA40w crossed up early July, PIRS price slid a -3.40%. Since price and SMA40w lines crossed up late May, PIRS climbed $0.95 (26.46%).
Pieris stock price history
Pieris stock went public on January 2nd, 2015 with a price of $2.751. Since then, PIRS stock surged a 65.10%, with an average of 16.30% per year. If you had invested right after PIRS's IPO a $1,000 in Pieris stock in 2015, it would worth $651.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Pieris stock historical price chart
PIRS stock reached 52-week highs on July/29 at $6.04, and all-time highs 2018-02-13 with a price of 9.75.
Pieris stock price target is $6.30How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' PIRS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 3 price predictions for PIRS stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-30||Robert W. Baird||Downgrades||n/a||$5.00||-|
|2019-6-17||HC Wainwright||Set Price Target||n/a||$7.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Pieris Pharmaceuticals reported its latest financial data, posting a dazzling growth for the Earnings per Share (EPS). Analyst expected $-0.16 per share, but Pieris Pharmaceuticals posted $-0.21.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a dazzling gain of 15.14% to $29.10 million USD. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) plunged a -22.12% to -91.93%.
|2013||$12 M||-||$0.07 M0.5%||-|
|2014||$1,772 M||14,153.74%||$108 M6.1%||162,341.84%|
|2014||$5.37 M||-99.70%||$-9.85 M-183.6%||-109.16%|
|2015||$1,885 M||35,026.61%||$75 M4.0%||-863.05%|
|2015||$2.93 M||-99.84%||$-14.06 M-479.5%||-118.70%|
|2016||$1,892 M||64,438.72%||$40 M2.1%||-381.89%|
|2016||$5.83 M||-99.69%||$-22.80 M-391.0%||-157.53%|
|2017||$1,828 M||31,259.17%||$30 M1.6%||-232.15%|
|2017||$25 M||-98.62%||$-17.65 M-69.8%||-158.57%|
|2018||$29 M||15.14%||$-26.75 M-91.9%||51.61%|
Quarterly financial resultsPieris posted $4.91 million in revenues for 2018-Q4, a -41.11% less compared to previous quarter. Reported quarter earnings marked $-11.68 M with a profit margin of -237.73%. Profit margin plunged a -164.00% compared to previous quarter when profit margin was -73.73%. When comparing sales to same quarter last year, Pieris Pharmaceuticals sales marked a bloodcurdling decrease and plummed a -72.93%. Looking back to recent quarterly results, Pieris Pharmaceuticals posted 2 negative quarters in a row.
|2017-Q1||$1 M||-||$-7.99 M-596.3%||-|
|2017-Q2||$2 M||38.06%||$-10.08 M-544.9%||26.16%|
|2017-Q3||$4 M||112.28%||$-7.06 M-179.7%||-29.97%|
|2017-Q4||$18 M||362.21%||$7.49 M41.3%||-206.12%|
|2018-Q1||$4 M||-77.13%||$-8.71 M-209.9%||-216.33%|
|2018-Q2||$12 M||181.58%||$-0.20 M-1.7%||-97.67%|
|2018-Q3||$8 M||-28.62%||$-6.15 M-73.7%||2,931.03%|
|2018-Q4||$5 M||-41.11%||$-11.68 M-237.7%||89.86%|
Pieris ownershipWhen you are planning to invest in shares of a company, it's worth to review its ownership structure.
Pieris Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.23% of all shares.
In case of Pieris Pharmaceuticals stock, 72.84% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for PIRS stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Pieris:
|Market cap||$223.6 M||$0.0 M||$151.1 M||$305.3 M||$64.8 M|
|Total shares||49.3 M||0.0 M||39.2 M||95.7 M||11.0 M|
|Float shares||45.0 M||68.0 M||46.3 M||35.3 M||5.6 M|
|- Institutional holdings (%)||72.8%||0.0%||67.9%||21.0%||53.7%|
|- Insider holdings (%)||0.2%||0.0%||1.3%||41.4%||20.9%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$4.50 - $4.78|
|Average true range||$0.33|
|50d mov avg||$4.73|
|100d mov avg||$4.15|
|200d mov avg||$3.62|
Pieris performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked Aurinia Pharmaceuticals, Calithera Biosciences, CASI Pharmaceuticals and Champions Oncology as the bechmarking frame for Pieris stock.